Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Vivancos

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.
JAMA Oncology|April 27, 2023
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabCoralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, et al.
Nature Communications|November 12, 2015
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasmaLeticia De Mattos-Arruda, Regina Mayor, Charlotte K Y Ng, et al.
Nature Communications|March 1, 2023
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerAleix Prat, Fara Brasó-Maristany, Olga Martínez-Sáez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2022
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug EvaluationQueralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trialsAlice Rossi, Irene Braña, Maria Vieito, et al.
NPJ Precision Oncology|July 11, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling programHeura Domènech, Sara Simonetti, Paula Romero-Lozano, et al.
Nature Communications|July 11, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, et al.
Med (New York, N.Y.)|August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trialsAlberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Ebiomedicine|September 20, 2024
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancerAlexia Mirandola, Andrei Kudriavtsev, Catalina Isabel Cofre Muñoz, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.
JAMA Oncology|April 27, 2023
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabCoralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, et al.
Nature Communications|November 12, 2015
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasmaLeticia De Mattos-Arruda, Regina Mayor, Charlotte K Y Ng, et al.
Nature Communications|March 1, 2023
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerAleix Prat, Fara Brasó-Maristany, Olga Martínez-Sáez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2022
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug EvaluationQueralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trialsAlice Rossi, Irene Braña, Maria Vieito, et al.
NPJ Precision Oncology|July 11, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling programHeura Domènech, Sara Simonetti, Paula Romero-Lozano, et al.
Nature Communications|July 11, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, et al.
Med (New York, N.Y.)|August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trialsAlberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Ebiomedicine|September 20, 2024
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancerAlexia Mirandola, Andrei Kudriavtsev, Catalina Isabel Cofre Muñoz, et al.
Pageof 11